<p>Lifecare ASA has submitted updated documentation to the Norwegian Medical Products Agency (NoMA) as part of its application to initiate a first-in-human clinical study of its implantable continuous glucose monitoring (CGM) system. The regulatory review process has resumed following this submission, addressing procedural and technical clarifications previously requested by NoMA. The agency has 26 review days remaining to complete its assessment and issue a decision, with a final outcome expected within the first quarter of 2026, pending any further clarification requests. The planned clinical study will evaluate the accuracy and clinical performance of Lifecare’s CGM system at the University of Bergen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecare ASA published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Lifecare ASA Submits Updated Documentation to NoMA for First-in-Human CGM Study Review